Antibody-drug conjugates(ADCs)represent an emerging anticancer therapeutic strategy that combines the high specificity of monoclonal antibodies with the lethality of highly cytotoxic drugs to fully leverage the advantages of tar-geted therapies.Compared with traditional chemotherapy drugs,ADCs can not only accurately identify tumor targets,but al-so achieve rapid delivery of drugs into tumor cells,providing higher therapeutic efficacy while reducing systemic toxic side effects.ADCs have shown excellent therapeutic effect in a variety of cancer types,and its research and application in the treatment of non-small cell lung cancer has also attracted much attention.This paper reviews the research status and pros-pects of ADCs in the treatment of non-small cell lung cancer.
国家科技期刊平台
NSTL
万方数据
